Why Attend the 2nd Tumour Models Summit Malmö Summit?
The Nordic oncology landscape is rapidly advancing, driven by strong investment in precision medicine and advanced therapeutics. Sweden alone is projected to see its precision oncology market exceed USD 2 billion by 2030, underscoring the region’s accelerating demand for translationally relevant preclinical models. This surge in innovation makes the Nordics a critical arena for advancing tumour model development and improving preclinical decision‑making for next‑generation oncology assets.
Part of the world-renowned Tumor Models events series, the 2nd Tumour Models Summit Malmö returns as the must-attend meeting for preclinical, translational, discovery, pharmacology, and biology teams striving to refine model‑selection strategies. This is the opportune moment to dissect comparative in vitro, in vivo, and ex vivo system performance, evaluate model fidelity against clinical outcomes; and refine predictive workflows that improve R&D efficiency and systematically de‑risk oncology assets prior to IND‑enabling studies.
Unmissable Event Highlights You Just Can’t Miss
1
Validate the translational relevance of complex in vitro 3D models with Roche by combining in vitro 3D model data with in vivo data to empower predictability power and de-risk preclinical development
2
Evaluate methods to better interpret in vivo model data with Orion Pharma to improve model predictive accuracy and empower small molecule and immune-oncology candidate development
3
Elevate immunocytokine development with Bright Peak Therapeutics by leveraging the right tumour models to decode mechanisms of action of and drive more predictive efficacy insights
4
Examine proven strategies to select, optimise and leverage xenograft models with Adcendo to tackle ADC payload toxicity and empower dosing strategies for underserved patient populations
5
Supercharge IO target validation with Hervolution Therapeutics by integrating syngeneic, xenograft and organoid models to elucidate mechanisms of action and sharpen translational strategy
What's New for 2026?
80%
New Speaker Faculty & New to the Tumour Models Meetings
60%
Of Case Studies Featuring New Model Types
58%
New Companies Represented on the Expert Speaker Faculty
Explore the Full Event Guide
- Free* to attend for biotech & pharma
- 70+ tumour modelling experts from biopharma based in the Nordics, Poland, Czechia, Germany, Austria and Switzerland
- Dedicated networking with decision-makers through roundtables, panels, and structured networking sessions
- Data-driven drug developer case studies on in vitro, complex in vitro, in vivo & more across multiple indications & modalities including ADCs, bispecifics, vaccines, cell therapy, and small molecules
- The only meeting in the Nordics uniting biotech, pharma, and model providers to master cutting‑edge tumour modelling, sharpen vendor selection, and confidently de‑risk preclinical assets
Attending Companies Include
Explore the Agenda
Hear the latest preclinical and translational data on tumour modelling, and gain first-hand insight into innovations on modelling for in vitro, in vivo, complex in vitro and more across multiple modalities.
Partner With Us
Position yourself as the partner of choice amongst leading model developers and solution providers to ensure your brand is at the heart of biopharma deals and collaborations.
Join Nordic Oncology Industry Experts
Connect with preclinical, translational, discovery, pharmacology, and biology drug developers from the leading Nordic biopharma companies through focused presentations, panels, and networking designed to spark meaningful scientific and commercial conversations.